John E. Schurig

938 total citations
30 papers, 693 citations indexed

About

John E. Schurig is a scholar working on Oncology, Molecular Biology and Toxicology. According to data from OpenAlex, John E. Schurig has authored 30 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Toxicology. Recurrent topics in John E. Schurig's work include Cancer Treatment and Pharmacology (7 papers), Bioactive Compounds and Antitumor Agents (6 papers) and Metal complexes synthesis and properties (5 papers). John E. Schurig is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Bioactive Compounds and Antitumor Agents (6 papers) and Metal complexes synthesis and properties (5 papers). John E. Schurig collaborates with scholars based in United States, Germany and United Kingdom. John E. Schurig's co-authors include William T. Bradner, William C. Rose, Jean F. Vollano, Salaam Al-Baker, James C. Dabrowiak, William A. Remers, Bhashyam S. Iyengar, R L Cavanagh, J P Buyniski and Joseph J. Catino and has published in prestigious journals such as Journal of Medicinal Chemistry, Pharmacology Biochemistry and Behavior and Cancer Treatment Reviews.

In The Last Decade

John E. Schurig

30 papers receiving 637 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John E. Schurig United States	16	272	219	199	125	110	30	693
Kazunari Nakao Japan	18	179 0.7×	133 0.6×	170 0.9×	215 1.7×	54 0.5×	60	834
Thomas Buhl Switzerland	18	179 0.7×	314 1.4×	294 1.5×	78 0.6×	26 0.2×	25	879
A. M. Creighton United Kingdom	11	154 0.6×	218 1.0×	86 0.4×	24 0.2×	29 0.3×	18	502
Ola Epemolu United Kingdom	17	145 0.5×	472 2.2×	70 0.4×	111 0.9×	23 0.2×	29	912
Glenda E. Bilder United States	15	102 0.4×	393 1.8×	204 1.0×	124 1.0×	22 0.2×	26	922
Laure Eloy France	18	121 0.4×	281 1.3×	275 1.4×	133 1.1×	21 0.2×	32	1.1k
Minu Dutia United States	14	123 0.5×	429 2.0×	336 1.7×	65 0.5×	31 0.3×	21	908
Mario Turriziani Italy	20	332 1.2×	454 2.1×	89 0.4×	91 0.7×	58 0.5×	39	1.2k
Arzu Yılmaztepe Oral Türkiye	13	152 0.6×	190 0.9×	94 0.5×	67 0.5×	46 0.4×	25	618
Naina Patel United Kingdom	18	178 0.7×	482 2.2×	73 0.4×	112 0.9×	30 0.3×	32	1.1k

Countries citing papers authored by John E. Schurig

Since Specialization

Citations

This map shows the geographic impact of John E. Schurig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Schurig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Schurig more than expected).

Fields of papers citing papers by John E. Schurig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Schurig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Schurig. The network helps show where John E. Schurig may publish in the future.

Co-authorship network of co-authors of John E. Schurig

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Schurig. A scholar is included among the top collaborators of John E. Schurig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Schurig. John E. Schurig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rose, William C., Alfred R. Crosswell, John E. Schurig, & Anna Maria Casazza. (1993). Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemotherapy and Pharmacology. 32(3). 197–203. 26 indexed citations

Bradner, William T., et al.. (1990). Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyidithio) ethyl] mitomycin C (BMY-25067). Investigational New Drugs. 8(S1). S1–S7. 8 indexed citations

Al-Baker, Salaam, et al.. (1990). Antitumor and DNA-binding properties of a group of oligomeric complexes of platinum(II) and platinum(IV). Journal of Medicinal Chemistry. 33(8). 2184–2188. 14 indexed citations

Hollis, L. Steven, Arthur V. Miller, Alan R. Amundsen, John E. Schurig, & Eric Stern. (1990). cis-Diamineplatinum(II) complexes containing phosphono carboxylate ligands as antitumor agents. Journal of Medicinal Chemistry. 33(1). 105–111. 22 indexed citations

Schurig, John E., William C. Rose, Hideo Kamei, et al.. (1990). Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent. Investigational New Drugs. 8(1). 7–15. 12 indexed citations

Schurig, John E., William T. Bradner, George A. Basler, & William C. Rose. (1989). Experimental antitumor activity of BMY-28090, a new antitumor antibiotic. Investigational New Drugs. 7(2-3). 173–178. 10 indexed citations

Rose, William C., et al.. (1988). Correlation of in vitro cytotoxicity with preclinical in vivo antitumor activity.. PubMed. 8(3). 355–67. 9 indexed citations

Stringfellow, Dale A. & John E. Schurig. (1987). The search for more active and less toxic mitomycin and etoposide analogs. Cancer Treatment Reviews. 14(3-4). 291–295. 6 indexed citations

Vollano, Jean F., Salaam Al-Baker, James C. Dabrowiak, & John E. Schurig. (1987). Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. Journal of Medicinal Chemistry. 30(4). 716–719. 61 indexed citations

10.

Bradner, William T., et al.. (1985). Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.. PubMed. 45(12 Pt 1). 6475–81. 14 indexed citations

11.

Bradner, William T., et al.. (1984). Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.. PubMed. 44(12 Pt 1). 5619–23. 7 indexed citations

12.

Iyengar, Bhashyam S., et al.. (1984). Mitomycin C analogs with aryl substituents on the 7-amino group. Journal of Medicinal Chemistry. 27(5). 701–708. 27 indexed citations

13.

Rose, William C., et al.. (1983). Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.. PubMed. 43(4). 1504–10. 24 indexed citations

14.

Iyengar, Bhashyam S., et al.. (1983). Mitomycin C and porfiromycin analogs with substituted ethylamines at position 7. Journal of Medicinal Chemistry. 26(1). 16–20. 22 indexed citations

15.

Schurig, John E., et al.. (1982). Antiemetic activity of butorphanol against cisplatin-induced emesis in ferrets and dogs.. PubMed. 66(10). 1831–5. 15 indexed citations

16.

Siminoff, Paul, et al.. (1982). BL-5255. International Archives of Allergy and Immunology. 67(2). 101–108. 7 indexed citations

17.

Rose, William C., et al.. (1982). Antitumor activity and toxicity of cisplatin analogs.. PubMed. 66(1). 135–46. 46 indexed citations

18.

Crooke, Stanley T., et al.. (1981). Tallysomycin, A Third Generation Bleomycin Analog. Recent results in cancer research. 76. 83–90. 1 indexed citations

19.

Bradner, William T. & John E. Schurig. (1981). Toxicology screening in small animals. Cancer Treatment Reviews. 8(2). 93–102. 27 indexed citations

20.

Schurig, John E., R L Cavanagh, & J P Buyniski. (1978). Effect of butorphanol and morphine on pulmonary mechanics, arterial blood pressure and venous plasma histamine in the anesthetized dog.. PubMed. 233(2). 296–304. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact